Garuda Therapeutics is thrilled to announce that we have successfully raised $47 million in our latest funding round, a significant milestone that will accelerate our mission to revolutionize blood stem cell transplants. Our cutting-edge platform technology is designed to eliminate the reliance on donor or patient cells, allowing for the production of off-the-shelf, self-renewing blood stem cells. This breakthrough holds the potential to provide patients with expedited and widespread access to consistent, durable, and HLA-compatible transgene-free therapies—a game changer in the landscape of regenerative medicine. With this new capital, we aim to enhance our research and development efforts, advance our clinical trials, and expedite the journey towards bringing potentially curative therapies to the over 120 diseases that can benefit from blood stem cell transplants, including various types of cancers and genetic disorders. The funding will also support the expansion of our team and infrastructure, laying the groundwork for future innovations in our therapeutic offerings. We are incredibly grateful for the trust and support from our investors, and we are excited to embark on this new phase of growth. At Garuda Therapeutics, we believe that our innovative approach will redefine standard care and significantly improve the quality of life for countless patients, moving us one step closer to a world where no one has to wait for a compatible donor again. For more details about our technology and vision, please visit us at [Garuda Therapeutics](https://garudatx.com).
Revolutionizing Blood Stem Cell Transplants: Garuda Therapeutics Secures $47 Million in Funding
Get the full Garuda Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Emphere
AI remediation for code, containers, and cloud.
$2.1M Pre-seed
today
Breaze Delivery
Scale your business with branded ordering apps, integrated with the Breaze Driver Network for on-demand deliveries.
$1.2M Seed
today
SamBoad
SamBoad began its journey in 2014 as SamBoad Ventures, founded by Samuel Kwame Boadu. Initially launched as a sole proprietorship focused on mobile money and agency services, the company quickly established itself as a trusted player in Ghana’s mobile financial services industry. By 2021, SamBoad Ventures had evolved, expanding its services and rebranding as SamBoad Holdings Ltd, a multifaceted Holding company with a corporate structure and two distinct subsidiaries and divisions (Business Names/Entreprises), alongside a foundation to support community health and youth development. SamBoad, maintaining your vision..
$1.0M Seed
today
QuantX Labs
QuantX Labs is the premier, sovereign provider of high precision timing and sensor products used in defence, space and critical infrastructure. Our specialised team have more than 70 years combined experience in the innovation and development of precision measurement devices. Our current focus is on three programs: • Precision clocks and oscillators - Our flagship product – Cryoclock - is the world’s most precise clock – and is being developed for deployment into the ADF’s JORN Defence Radar. • Optical Atomic Clocks – a ground-breaking development of a next generation space atomic clock based on optical technology. • Quantum magnetometers - developed to sense extremely small changes in magnetic field due to ferrous material. These leading-edge technologies are just the beginning of the innovative solutions being designed for a range of sovereign and global applications including resilient position, navigation and timing services.
$5.0M Seed
today
Handshake
Handshake is the career network for the AI economy. 20 million knowledge workers, 1,600 educational institutions, 1 million employers (including 100% of the Fortune 500), and every foundational AI lab trust Handshake to power career discovery, hiring, and upskilling, from freelance AI training gigs to first internships to full-time careers and beyond.
$2.4M Unknown
1 day ago